A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Completed · Phase 1

Conditions studied: Advanced Malignancy, Cancer, Oncology, Oncology Patients, Acute Myeloid Leukemia

In brief

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

Key facts

Study ID

NCT02016729

Run by

Kartos Therapeutics, Inc.

People needed

36

Starts

2014-04-01

Expected to finish

2017-07-31

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women > 18 years old
• Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory to standard treatment, for which no standard therapy is available or the subject refuses standard therapy
• Ability to take oral medications and willing to record daily adherance to investigational product
• Adequate hematological, renal, hepatic, and coagulation laboratory assessments

You may not qualify if…

• Active infection requiring intravenous (IV) antibiotics
• Prior participation in an investigational study (procedure or device) within 21 days of study day 1
• Major surgery within 28 days of study day 1
• Anti-tumor therapy within 14 days of study day 1

Where it is running

• Research Site — Birmingham, Alabama, United States
• Research Site — Buffalo, New York, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Salt Lake City, Utah, United States
• Research Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.